Hepatocellular carcinoma: Risk factors, diagnosis and treatment

Open Access Macedonian Journal of Medical Sciences

Volumn 3, Issue 4, 2015, Pages 732-736

  Janevska, Dafina ^a   Chaloska Ivanova, Viktorija ^a   Janevski, Vlado ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Diagnosis; Hepatocellular carcinoma; Management; Review article; Risk factors

Indexed keywords

AFLATOXIN; ALPHA FETOPROTEIN; BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA METHYLTRANSFERASE 1; K RAS PROTEIN; PROTEIN P16; TRANSFORMING GROWTH FACTOR BETA;

ALCOHOL CONSUMPTION; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CANCER THERAPY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; ECHOGRAPHY; GENE MUTATION; HEPATITIS B; HETEROZYGOSITY LOSS; HUMAN; LIVER CELL CARCINOMA; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; RISK FACTOR;

EID: 85027416163     PISSN: None     EISSN: 18579655     Source Type: Journal    
DOI: 10.3889/oamjms.2015.111     Document Type: Article

References (37)

1. El-Serag HB. Hepatocellular Carcinoma. N Engl J Med. 2011;365:1118-27. http://dx.doi.org/10.1056/NEJMra1001683 PMid:21992124
2. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Annals of Oncology. 1997;8:117-136. http://dx.doi.org/10.1023/A:1008285123736 PMid:9093719
3. El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007;132:2557–2576 http://dx.doi.org/10.1053/j.gastro.2007.04.061 PMid:17570226
4. Heidelbaugh JJ., Bruderly M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. Am Fam Physician. 2006;74:756–762 PMid:16970019
5. Sanyal AJ, Yoon SK, Lencioni R. The Etiology of Hepatocellular Carcinoma and Consequences for Treatment. The Oncologist. 2010;15(suppl 4):14–22. http://dx.doi.org/10.1634/theoncologist.2010-S4-14 PMid:21115577
6. Munoz N, Bosch X. Epidemiology of hepatocellular carcinoma. In: Neoplasms of the Liver, Okuda, K, Ishak, KG (Eds), Springer, Tokyo 1989: p. 3.
7. Venook AP, Papandreou C, Furuse J, and Ladrón de Guevara L. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective The Oncologist. 2010;15:5-13.
8. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. http://dx.doi.org/10.3322/canjclin.55.2.74 PMid:15761078
9. Gurtsevitch VE. Human oncogenic viruses: Hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc). 2008; 73:504–513. http://dx.doi.org/10.1134/S0006297908050039
10. Szabó E, Páska C, Kaposi Novák P. et al. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol Oncol Res. 2004; 10:5–11. http://dx.doi.org/10.1007/BF02893401 PMid:15029254
11. Alan D, Herbst BA, and Reddy KR. Risk Factors for Hepatocellular Carcinoma. Clinical Liver Disease. 2012;1(6):??.
12. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. World Gastroenterology Organisation guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis. 2010;19:311–317. http://dx.doi.org/10.1097/mcg.0b013e3181d46ef2
13. Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323–331. http://dx.doi.org/10.1093/aje/155.4.323 PMid:11836196
14. Sheikh MY, Choi J, Qadri I et al. Hepatitis C virus infection: Molecular pathways to metabolic syndrome. Hepatology. 2008;47:2127–2133. http://dx.doi.org/10.1002/hep.22269 PMid:18446789
15. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 2009;20:353-357. http://dx.doi.org/10.1093/annonc/mdn565 PMid:18723550
16. Ascha MS, Hanouneh IA, Lopez R, Abu-Rajab Tamini T, Feldstein AF, Zein NN. The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis. Hepatology. 2010;51(6): 1972-8. http://dx.doi.org/10.1002/hep.23527 PMid:20209604
17. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369-80. http://dx.doi.org/10.1016/j.cgh.2005.12.007 PMid:16527702
18. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323-31. http://dx.doi.org/10.1093/aje/155.4.323 PMid:11836196
19. Raphael SW, Yangde Z, and YuXiang C. Hepatocellular Carcinoma: Focus on Different Aspects of Management ISRN Oncology. 2012;Article ID 421673:12 pages.
20. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429. http://dx.doi.org/10.1038/350429a0 PMid:1672732
21. Hirohashi S, Blum HE, Ishak KG, Deugnier Y, Kojiro M, Laurent Puig P, Wanless IR, Fischer HP, Theise ND, Sakamoto M, Tsukuma H. Hepatocellular carcinoma in World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Digestive System IARCPress Lyon, 2000
22. El-Serag HB, Marrero JA, Rudolph L, and Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134(6):1752–1763. http://dx.doi.org/10.1053/j.gastro.2008.02.090 PMid:18471552
23. Somi MH. Hepatocellular Carcinoma. Hepatitis Monthly. 2005; 5(3): 65-76
24. Ryder SD. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003; 52(suppl 3):iii1–iii8. http://dx.doi.org/10.1136/gut.52.suppl_3.iii1 PMid:12692148 PMCid:PMC1867754
25. Bolog N, Andreisek G, Oancea I, and Mangrau A. CT and MR imaging of hepatocellular carcinoma. Journal of Gastrointestinal and Liver Diseases. 2011;20(2):181–189. PMid:21725516
26. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010; 15;31(4):461-76.
27. Marrero JA, Hussain HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005;11: 281–9. http://dx.doi.org/10.1002/lt.20357 PMid:15719410
28. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36. http://dx.doi.org/10.1002/hep.20933 PMid:16250051
29. Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies. Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, and Di Carlo I. BioMed Research International. 2014;Article ID 203693:15 pages.
30. Pons F, Varela M, and Llovet MJ. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005; 7(1):35-41. http://dx.doi.org/10.1080/13651820410024058 PMid:18333159 PMCid:PMC2023920
31. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-943. http://dx.doi.org/10.1016/j.jhep.2011.12.001 PMid:22424438
32. Bruix J, Shereman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53(3):1020–1022. http://dx.doi.org/10.1002/hep.24199 PMid:21374666 PMCid:PMC3084991
33. Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115-4127. http://dx.doi.org/10.3748/wjg.v20.i15.4115 PMid:24764650 PMCid:PMC3989948
34. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008;47:82-89. http://dx.doi.org/10.1002/hep.21933 PMid:18008357
35. Wang P, Sheng L, Mang G, Wang H, Huang X, Yan X, Yang X and Pei R. Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma. Mol Clin Oncol. 2014; 2(2): 203–206. PMid:24649333 PMCid:PMC3917780
36. Greten T F, Papendorf F, Bleck J S, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanskiand M, Manns M P. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. BJC. 2005;92:1862–1868. http://dx.doi.org/10.1038/sj.bjc.6602590 PMid:15870713 PMCid:PMC2361778
37. Hirohashi S, Blum HE, Ishak KG, Deugnier Y, Kojiro M, Laurent Puig P, Wanless IR, Fischer HP, Theise ND, Sakamoto M, Tsukuma H. Hepatocellular carcinoma in World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Digestive System IARC Press:Lyon, 2000.